Theracarb Inc. is a private Canadian biotechnology company developing and commercializing technologies derived from the Alberta Ingenuity Center for Carbohydrate Sciences (AICCS), a research center funded by Alberta Ingenuity, a $1B endowed fund. Theracarb's development programs span vaccine and therapeutic treatment options in two core disease areas: infectious diseases and neurodegenerative diseases.

Theracarb News

April 24, 2009:
TheraCarb Inc. Receives Notice of Allowance for US Patent View.

November 6, 2008:
Dr. Murray Ratcliffe joins as TheraCarb Chief Operating Officer View.

October 22, 2008:
TheraCarb Inc. Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research View.

More...